Jun 26, 2026 09:00AM
Jun 26, 2026 09:00AM
Jun 19, 2026 02:00AM
Jun 15, 2026 09:24AM
Jun 14, 2026 04:35PM
Jun 14, 2026 04:35PM
Jun 13, 2026 06:01AM NASDAQ: INCY shows 25% reduction in disease progression risk in lymphoma study
Jun 13, 2026 06:00AM
Jun 8, 2026 07:00AM
Jun 8, 2026 07:00AM
Jun 4, 2026 08:06AM
Jun 4, 2026 08:05AM
Jun 1, 2026 02:53AM
May 30, 2026 08:00AM Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in P
May 12, 2026 09:30AM
May 7, 2026 08:50AM
May 7, 2026 08:50AM
May 3, 2026 12:00PM
May 1, 2026 05:28PM
May 1, 2026 05:28PM
Apr 29, 2026 10:15AM Incyte (INCY) PT Raised to $123 at Stifel Following 'Solid' Q1 Results
Apr 28, 2026 07:00AM
Apr 28, 2026 07:00AM
Apr 28, 2026 07:00AM
Apr 23, 2026 05:48AM
Apr 23, 2026 03:00AM
Apr 21, 2026 10:00AM
Apr 21, 2026 10:00AM Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 7, 2026 12:26PM
Apr 7, 2026 07:30AM
Apr 2, 2026 07:01AM
Apr 2, 2026 07:01AM
Mar 30, 2026 10:19AM
Mar 30, 2026 04:21AM
Mar 28, 2026 03:00PM Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Mar 25, 2026 09:13AM
Mar 24, 2026 04:02PM
Mar 20, 2026 10:00AM
Mar 17, 2026 07:30AM
Mar 17, 2026 07:30AM
Mar 9, 2026 08:00AM
Feb 27, 2026 08:13AM CHMP recommends Eli Lilly's Olumiant for teens with severe hair loss
Feb 27, 2026 08:11AM
Feb 19, 2026 05:31PM
Feb 17, 2026 10:48AM
Feb 16, 2026 05:31PM
Feb 10, 2026 07:00AM
Jan 30, 2026 09:29AM
Jan 30, 2026 09:29AM Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
Jan 5, 2026 01:33PM

324,401 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All